Want to see HCWB full AI Analyst Report?
Top Page
HCW Biologics
(NASDAQ:HCWB)
Select Model
Select Model
Rating:43Neutral
Price Target:
$2.50
▲(0.00% Upside)
Action:Reiterated
Date:08/17/26
The score is primarily constrained by weak financial performance (persistent losses and significant cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events provide some offset via encouraging trial updates and balance-sheet/legal cleanup, but ongoing financing needs and listing-risk concerns keep the overall risk profile elevated.
Positive Factors
Early Clinical Validation
Preliminary Phase 1 results provide early human validation for HCW9302’s Treg-focused mechanism, with activity and tolerability supporting dose selection and potential expansion into broader autoimmune and inflammatory indications.
Negative Factors
Persistent Cash Burn
Material negative operating and free cash flow shows that HCW’s development activities are not self-funding. Continued cash consumption will require additional capital or partnerships, increasing execution risk if funding becomes less available.
Read all positive and negative factors
Positive Factors
Negative Factors
Early Clinical Validation
Preliminary Phase 1 results provide early human validation for HCW9302’s Treg-focused mechanism, with activity and tolerability supporting dose selection and potential expansion into broader autoimmune and inflammatory indications.
Read all positive factors
HCW Biologics (HCWB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.63M
Dividend YieldN/A
Average Volume (3M)105.98K
Price to Earnings (P/E)―
Beta (1Y)1.50
Revenue Growth707.02%
EPS Growth70.52%
CountryUS
Employees35
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-22.55
Shares Outstanding1,836,324
10 Day Avg. Volume63,564
30 Day Avg. Volume105,978
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.74
Price to Sales (P/S)37.52
P/FCF Ratio-0.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.88
Revenue Forecast (FY)$900.00K
HCW Biologics Business Overview & Revenue Model
Company Description
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation ...
How the Company Makes Money
HCW Biologics does not appear to have a mature, product-sales-based revenue model typical of commercial-stage biopharmaceutical companies; instead, as a clinical-stage biotech, it is generally expected to fund operations primarily through capital ...
HCW Biologics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.72M | 54.23K | 2.57M | 2.84M | 6.72M | 0.00 |
| Gross Profit | 6.45M | 10.85K | 959.40K | 560.36K | 2.59M | 0.00 |
| EBITDA | -4.27M | -5.67M | -27.68M | -23.58M | -14.06M | -12.32M |
| Net Income | -4.92M | -7.96M | -30.02M | -24.99M | -14.90M | -12.86M |
Balance Sheet | ||||||
| Total Assets | 26.77M | 24.52M | 30.24M | 28.51M | 46.81M | 53.51M |
| Cash, Cash Equivalents and Short-Term Investments | 741.32K | 1.95M | 4.67M | 3.60M | 32.06M | 36.71M |
| Total Debt | 6.56M | 6.81M | 13.69M | 6.30M | 6.41M | 0.00 |
| Total Liabilities | 19.34M | 21.76M | 37.01M | 15.05M | 9.38M | 2.32M |
| Stockholders Equity | 7.43M | 2.76M | -6.77M | 13.46M | 37.43M | 51.19M |
Cash Flow | ||||||
| Free Cash Flow | -12.14M | -13.39M | -14.49M | -28.72M | -20.66M | -11.02M |
| Operating Cash Flow | -12.14M | -13.39M | -14.23M | -22.51M | -10.39M | -10.98M |
| Investing Cash Flow | 0.00 | 0.00 | -261.62K | 3.80M | 14.71M | -35.02M |
| Financing Cash Flow | 10.44M | 10.67M | 15.57M | -14.53K | 6.27M | 49.27M |
HCW Biologics Technical Analysis
Negative
2.50
Price Trends
4.74
Negative
4.81
Negative
6.91
Negative
Market Momentum
-0.49
Negative
30.27
Neutral
6.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HCWB, the sentiment is Negative. The current price of 2.5 is below the 20-day moving average (MA) of 3.06, below the 50-day MA of 4.74, and below the 200-day MA of 6.91, indicating a bearish trend. The MACD of -0.49 indicates Negative momentum. The RSI at 30.27 is Neutral, neither overbought nor oversold. The STOCH value of 6.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HCWB.
HCW Biologics Risk Analysis
HCW Biologics disclosed 51 risk factors in its most recent earnings report. HCW Biologics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
HCW Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $7.64M | -2.70 | -39.28% | ― | 33.30% | 40.59% | |
49 Neutral | $11.46M | -1.05 | -59.30% | ― | ― | 19.38% | |
45 Neutral | $5.93M | -0.74 | -131.35% | ― | -50.79% | -180.59% | |
43 Neutral | $4.63M | -0.12 | -102.39% | ― | 707.02% | 70.52% | |
42 Neutral | $3.26M | -0.18 | -204.27% | ― | ― | 68.91% | |
42 Neutral | $3.51M | -0.03 | -438.03% | ― | ― | 53.95% |
* Healthcare Sector Average
HCWB
HCW Biologics
2.13
-19.23
-90.03%
KPRX
Kiora Pharmaceuticals
2.59
-0.08
-3.00%
MTNB
Matinas BioPharma
0.20
-1.50
-88.06%
XBIO
Xenetic Biosciences
3.25
0.43
15.25%
ADXN
Addex Therapeutics
5.57
-3.16
-36.20%
CLDI
Calidi Biotherapeutics
1.27
-46.73
-97.35%
HCW Biologics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
HCW Biologics Announces $1.6 Million Private Placement Financing
Positive
Jul 29, 2026
On July 29, 2026, HCW Biologics Inc. entered into a securities purchase agreement for a $1.6 million private placement involving 618,682 units, each comprising common stock or a pre-funded warrant and the right to receive a common warrant, with pr...
Business Operations and StrategyFinancial DisclosuresLegal Proceedings
HCW Biologics Resolves Disputes, Clears Miramar Property Liens
Positive
Jul 1, 2026
In the quarter ending June 30, 2026, HCW Biologics will recognize the settlement and extinguishment of $2.8 million in disputed accounts payable, following the June 26, 2026 voluntary dismissal with prejudice of crossclaims by BI Contractors and t...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
HCW Biologics Regains Nasdaq Compliance, Plans Reverse Split
Neutral
Jun 30, 2026
On June 29, 2026, HCW Biologics reported that a Nasdaq Hearings Panel determined the company had regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2). As a result, HCW Biologics is now in compliance w...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
HCW Biologics Announces 1-for-6 Reverse Stock Split
Neutral
Jun 26, 2026
HCW Biologics’ shareholders authorized, and its board approved, a 1-for-6 reverse stock split of the company’s common stock in June 2026, with the split scheduled to take effect at 12:01 a.m. Eastern on June 30, 2026, and trading on a ...
Business Operations and StrategyProduct-Related Announcements
HCW Biologics Reports Positive Phase 1 Alopecia Trial Data
Positive
Jun 16, 2026
On June 16, 2026, HCW Biologics reported positive preliminary human data from the first two dose cohorts of its dose-escalating Phase 1 trial of HCW9302 monotherapy in patients with alopecia areata, with all three participants in the 3 micrograms/...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
HCW Biologics Shareholders Approve Governance and Capital Measures
Positive
Jun 15, 2026
On June 15, 2026, HCW Biologics held its 2026 annual meeting of stockholders, where shareholders elected Lisa M. Giles and Rick S. Greene as Class II directors for terms expiring at the 2029 annual meeting and ratified the appointment of Crowe LLP...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
HCW Biologics Wins Nasdaq Extension to Avoid Delisting
Negative
Jun 1, 2026
HCW Biologics Inc. disclosed that on March 26, 2026, it received notice from Nasdaq that its securities had failed to meet the $1 minimum bid price requirement for 30 consecutive business days, and because it had executed a 1-for-40 reverse stock ...
Business Operations and StrategyProduct-Related Announcements
HCW Biologics Reclaims Key Cell Therapy License Rights
Positive
May 27, 2026
On May 27, 2026, HCW Biologics announced that it had exercised its option, effective May 21, 2026, to terminate Wugen Inc.’s exclusive worldwide ex vivo license to its HCW9201 and HCW9206 molecules, regaining full rights to these commercial-...
Business Operations and StrategyPrivate Placements and Financing
HCW Biologics Raises $4M in Private Placement Financing
Positive
May 21, 2026
On May 21, 2026, HCW Biologics Inc. entered into a private securities purchase agreement with accredited healthcare-focused investors, issuing 2,846,975 units priced at $1.405 each for gross proceeds of about $4.0 million. Each unit comprised eith...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.